Phillip Md Et Al Frost Acquires 163,997 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPKGet Free Report) CEO Phillip Md Et Al Frost purchased 163,997 shares of the stock in a transaction on Friday, May 17th. The shares were acquired at an average price of $1.29 per share, for a total transaction of $211,556.13. Following the transaction, the chief executive officer now directly owns 211,132,222 shares of the company’s stock, valued at approximately $272,360,566.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, March 18th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were acquired at an average price of $0.87 per share, for a total transaction of $435,000.00.
  • On Thursday, March 14th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were purchased at an average cost of $0.89 per share, with a total value of $445,000.00.
  • On Tuesday, March 12th, Phillip Md Et Al Frost bought 600,000 shares of OPKO Health stock. The shares were purchased at an average cost of $0.93 per share, with a total value of $558,000.00.
  • On Wednesday, February 28th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were purchased at an average cost of $0.99 per share, with a total value of $495,000.00.
  • On Wednesday, February 21st, Phillip Md Et Al Frost bought 1,000,000 shares of OPKO Health stock. The shares were purchased at an average cost of $0.99 per share, with a total value of $990,000.00.

OPKO Health Stock Performance

Shares of OPKO Health stock opened at $1.32 on Friday. OPKO Health, Inc. has a one year low of $0.85 and a one year high of $2.24. The company has a market cap of $920.03 million, a price-to-earnings ratio of -3.77 and a beta of 1.81. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.62 and a current ratio of 1.91. The business’s 50 day moving average price is $1.19 and its 200 day moving average price is $1.22.

OPKO Health (NASDAQ:OPKGet Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). OPKO Health had a negative return on equity of 17.89% and a negative net margin of 31.44%. The company had revenue of $173.70 million for the quarter, compared to analysts’ expectations of $182.99 million. During the same quarter in the previous year, the business posted ($0.02) EPS. The business’s quarterly revenue was down 26.9% compared to the same quarter last year. On average, research analysts predict that OPKO Health, Inc. will post -0.35 EPS for the current year.

Institutional Investors Weigh In On OPKO Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. raised its position in OPKO Health by 300.4% in the third quarter. Invesco Ltd. now owns 5,164,180 shares of the biotechnology company’s stock valued at $8,263,000 after purchasing an additional 3,874,519 shares during the period. SG Americas Securities LLC raised its position in OPKO Health by 19.3% in the fourth quarter. SG Americas Securities LLC now owns 244,294 shares of the biotechnology company’s stock valued at $369,000 after purchasing an additional 39,459 shares during the period. EP Wealth Advisors LLC raised its position in OPKO Health by 140.3% in the third quarter. EP Wealth Advisors LLC now owns 30,900 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 18,041 shares during the period. Charles Schwab Investment Management Inc. raised its position in OPKO Health by 7.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 5,549,946 shares of the biotechnology company’s stock valued at $8,880,000 after purchasing an additional 405,106 shares during the period. Finally, Choreo LLC purchased a new stake in OPKO Health in the fourth quarter valued at $106,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on OPK. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of OPKO Health in a report on Wednesday, May 8th. StockNews.com raised OPKO Health to a “sell” rating in a report on Thursday. Piper Sandler reiterated an “overweight” rating and set a $5.00 price objective on shares of OPKO Health in a research report on Monday, April 1st. Finally, Barrington Research reiterated an “outperform” rating and set a $1.50 price objective on shares of OPKO Health in a research report on Monday, April 1st.

Check Out Our Latest Stock Report on OPKO Health

OPKO Health Company Profile

(Get Free Report)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

Featured Articles

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.